Coronavirus information for Feinberg.

Skip to main content

Movement Disorder Trials

As part of an academic medical center, the Division of Movement Disorders at Northwestern University Feinberg School of Medicine aims to improve human health through scientific research. Clinical trials test or study drugs, surgical procedures, medical devices or interventions with human subjects. They look to determine their safety and effectiveness in relation to treating specific diseases. Clinical trials are part of clinical research and are at the heart of all medical advances.

The following searchable list includes all the movement disorder clinical trials currently looking for participants.

Trials
The Parkinson’s Progression Markers Initiative (PPMI)
This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. …
This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.
Genetic Cohort-PD Subjects
• Have at least two of the following: resting tremor, slowness of movement, muscle rigidity
• Parkinson disease diagnosis for 7 years or less
• Male or female 18 years or older
• Confirmation of LRRK2, GBA, or SNCA genetic mutation
• Willing to undergo genetic testing

Genetic Cohort-Unaffected Subjects
• 50 years or older with LRRK2/GBA mutation or first degree relative with LRRK2/GBA mutation
• Willing to undergo genetic testing
OR
• 30 years or older with SNCA mutation or first degree relative with SNCA mutation
• Willing to undergo genetic testing
Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT01141023 STU00031752
More Info
Copy
Parkinson’s Disease and Movement Disorders Center Biorepository
This is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the regi…
This is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the registry is to identify factors that either cause these neurologic conditions or increase one’s risk for developing them. Samples collected for this biorepository include a blood sample (or a saliva sample) and a skin biopsy. Participants may choose to donate one or both samples.
• Diagnosis of a movement disorder
• Male or female 5 years of age or older when diagnosed
• Genetic mutation related to a movement disorder
• Family members of patients with movement disorders
Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
STU00091585
More Info
Copy
Enroll-HD: A Prospective Registry Study in a Global Huntington’s Disease Cohort
The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers wil…
The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find new treatments for the disease. People from many countries contribute to Enroll-HD.
Individuals 18 yrs or older affected by Huntington's Disease (HD) or from a HD family or are a "community control" (a person who does not carry the HD genetic mutation that causes Huntington's disease and is not part of an HD family, but would like to participate in the study). Research visits are conducted yearly and will consists of a collection of medical and family history and biological samples.
Bega, DannyBega, Danny
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00203021
More Info
Copy
Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) to Study Natural History and Genetic Modifiers in Spinocerebellar Ataxia (SCA)
The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurolo…
The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to traditional clinician rating methods. The gene analysis is expected to establish a relationship, if any, between age at onset of disease and disease progression rates.
• Age 18 and older
• Presence of symptoms and signs of ataxia
• Molecular diagnosis of SCA 1, 2, 3, 6 either in the participant or an affected family member
• Willingness to participate in the study and ability to give informed consent.
Opal, PuneetOpal, Puneet
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
NCT01060371 STU00204294
More Info
Copy
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants with Early Parkinson’s Disease with a 6-Year All-Participants-On-Treatment Extension (PASADENA)
This is a multicenter, Phase II study to eva…
This is a multicenter, Phase II study to evaluate the effect of IV administration of RO7046015 in participants with early stage Parkinson's Disease (PD). Participants will be eligible if they have PD with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity) being present, without any other known or suspected cause of PD and are either untreated or treated with Azilect or Selegiline. The study will consist of two parts: a 52-week, treatment period of the study medication vs placebo (Part 1) after which eligible participants will continue into an all-participants-on-treatment (RO7046015) blinded to dose extension for an additional 52 weeks (Part 2).
*Men and women, aged 40 to 80 years inclusive, early PD , who were recently (< 2 years) diagnosed, and either untreated or treated with Azilect or Selegiline
Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03100149 STU00205125
More Info
Copy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease (Protocol #228PD201)
The primary objective of the study is to eva…
The primary objective of the study is to evaluate the clinical efficacy of BIIB054 via dose response using the change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score.

Diagnosed with Parkinson's disease (PD) within a maximum of 3 years prior to Screening.

Score of ≤2.5 on the Modified Hoehn and Yahr Scale.

Has not received any medication for the treatment of the motor symptoms of PD for at least 12 weeks prior to Day 1 and, in the opinion of the Investigator, is not expected to require PD treatment for at least 6 months following Day 1.

Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03318523 STU00206260
More Info
Copy
Clinical Trial Readiness for SCA1 and SCA3
Subjects must be 18-65 years of age with symptoms of ataxia or a diagnosis of SCA1 or SCA3 or have an affected family member. Subjects with a previous diagnosis of early stage SCA1 or SCA 3 may also be eligible. Subject must be able to undergo a MRI (brain…
Subjects must be 18-65 years of age with symptoms of ataxia or a diagnosis of SCA1 or SCA3 or have an affected family member. Subjects with a previous diagnosis of early stage SCA1 or SCA 3 may also be eligible. Subject must be able to undergo a MRI (brain scan) and not weigh over 300 lbs.
Subjects aged 18 to 65 with presence of symptomatic ataxic disease or asymptomatic mutation carrier or subjects with definite molecular diagnosis of SCA1 or SCA3 or another affected family member or Subjects of age >18 with previous diagnosis of early stage SCA1 and SCA3. Subjects must not make changes in physical/occupational therapy status within two months prior to enrollment. Subjects must not weigh over 300 lbs.
5) 6) No changes in sical/occupational therapy status within two months prior to enrolment
Opal, PuneetOpal, Puneet
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03487367 STU00206988
More Info
Copy
A Phase 3, Randomized, Rater-Blinded, Multi-Center Study to Evaluate the Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Patients with Wilson Disease Aged 12 Years and Older with an Extension Period of Up to 60 Months
The primary objective of this study is to eval…
The primary objective of this study is to evaluate the efficacy of the drug WTX101 administered for 48 weeks, compared to standard of care (SoC), on copper (Cu) control in subjects with Wilson's disease aged 18 and older.
Diagnosis of Wilson's Disease, Treatment for >28 days with chelation therapy, Zn therapy or a combination of chelator and Zn; willing to avoid the use of vitamins and/or minerals containing CU, Zn or Mo throughout the study, willing to undergo > 48-hour washout from current WD treatment
Bega, DannyBega, Danny
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03403205 STU00206921
More Info
Copy
A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients with Motor Fluctuations (Protocol #: IPX203-B16-02)
The study will consist of a 3-week, open-label IR CD-LD dose adjustment period; a 4-week, open-label…
The study will consist of a 3-week, open-label IR CD-LD dose adjustment period; a 4-week, open-label period for conversion to IPX203; followed by a 13-week double-blind treatment period with subjects randomized in a 1:1 ratio, to receive either IPX203 (with matching IR CD-LD placebo) or IR CD-LD (with matching IPX203 placebo).  The purpose is to evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) extended-release capsules (IPX203 ER CD-LD) in comparison to immediate release (IR) CD-LD in the treatment of CD-LD-experienced subjects with Parkinson's disease (PD) who have motor fluctuations.
Subjects with Parkinson's disease (PD) who have motor fluctuations and experience with carbidopa-levodopa medication.
Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03670953 STU00209650
More Info
Copy
A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson’s Disease (Protocol# 254PD101)
The purpose of study is to determine whether BIIB094 may improve PD symptoms in subjects with or…
The purpose of study is to determine whether BIIB094 may improve PD symptoms in subjects with or without changes in the LRRK2 gene. The study medication will be given as an injection into your back near the spinal cord. This iscalled an “intrathecal” injection.

2. Diagnosis of PD w/in 7yrs without motor fluctuationsor dyskinesia.

3. Not on any medication for PD or on stable therapy for 8weeks prior to screening.

Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03976349 STU00210196
More Info
Copy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntington Disease
The purpose of this research study is to evaluate the effectiveness of valbenazine to reduce chorea associated w…
The purpose of this research study is to evaluate the effectiveness of valbenazine to reduce chorea associated with Huntington disease (HD) and the safety and tolerability of valbenazine.

• Age 18 to 75 years of age.

• Diagnosis of motor manifest HD

• Genetic diagnosis of HD with CAG repeat ≥ 37

Bega, DannyBega, Danny
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT04102579 STU00210771
More Info
Copy
An Open-Label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson’s Disease Patients with Motor Fluctuations (IPX203-B16-03)

This is a 9-month, multicenter open-label safety extension study. The purpose of this study is to evaluate the long-term safety and clinical utility…

This is a 9-month, multicenter open-label safety extension study. The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of subjects with advanced Parkinson's disease (PD) who have motor fluctuations.

Subjects who have successfully completed Study IPX203-B16-02 [A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release (IR) Carbidopa-Levodopa (CD-LD) in Parkinson's Disease Patients with Motor Fluctuations] may have the opportunity to enroll in this open-label study.
Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03877510 STU00210565
More Info
Copy
A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients with Parkinson’s Disease with at Least One GBA1 Mutation (PROPEL, Protocol #: PRV-PD101)
PR001A is an investigational gene therapy product that is being developed for the treatment of PD in patient…
PR001A is an investigational gene therapy product that is being developed for the treatment of PD in patients with GBA1 mutations. The purpose of this study is to find out what effects PR001A has on Parkinson’s disease patients. Participants will be assigned to receive one dose of PR001A by injection into the cisterna magna (a large space at the base of the brain).

1. 40-75 years of age.

2. Diagnosis of PD with H&Y 3-4.

3. On stable PD therapy for 8 weeks prior to baseline.

4. At least 1 GBA gene mutation.

Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT04127578 STU00209947
More Info
Copy
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease
The purpose of study is to determine if NLY01 helps lessen symptoms and signs of early Parkinson’s disease and …
The purpose of study is to determine if NLY01 helps lessen symptoms and signs of early Parkinson’s disease and whether it slows the progression of Parkinson’s disease.

1. Subjects aged 30-80 yrs of age

2. Lessthan 5 yrs of PD symptom onset

3. Must not be taking any medication for PD treatment

Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT04154072 STU00211693
More Info
Copy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease
The purpose of this study is to evaluate the safety and effectiveness of the study drug, pridopidine,on everyda…
The purpose of this study is to evaluate the safety and effectiveness of the study drug, pridopidine,on everyday functioning and daily activities, as well as movement and behaviorin participants with early stage Huntington Disease (HD)

1. >25yrs of age.

2. Diagnosis of HD with CAG repeat > 36

Bega, DannyBega, Danny
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT04556656 STU00213780
More Info
Copy
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
TAK-071 is an investigational …
TAK-071 is an investigational drug that is being studied as a possible treatment for people withParkinson’s Disease who have a history of falls.

1.Subjects aged 40 to 75years who have a clinical diagnosis of PD.

2.Study partner supervisingand assisting with medication administration.

3.On stable medication for atleast 4 weeks.

4. At least 2 falls in the last 6 monthsprior to screening.

LaFaver, KathrinLaFaver, Kathrin
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT04334317 STU00212952
More Info
Copy
Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects with Wilson Disease

Given the limited information on the frequency and spectrum of disease manifestations and clinical course of Wilson disease, this study aims to assess the utility and feasibility of various assessments…

Given the limited information on the frequency and spectrum of disease manifestations and clinical course of Wilson disease, this study aims to assess the utility and feasibility of various assessments and biomarkers to inform endpoint selection for future clinical studies, better understand the relationship between biomarkers and potential clinical outcomes, and characterize the clinical presentation of Wilson disease.

UX701-CL001 is a clinical survey study for subjects with a confirmed diagnosis of Wilson disease (Figure 1). Subjects will complete assessments at the study site and at home to evaluate the clinical manifestations of Wilson disease in clinical and real-world environments. The study includes general assessments; patient- and clinician-reported outcome (PRO and CRO)

Bega, DannyBega, Danny
NCT04531189 STU00212962
More Info
Copy